Peptides, senolytics & the experiments
Frontier
The most interesting corner of the field, and the one where the gap between excitement and evidence is widest. Plausible mechanisms, striking animal data, thin human proof. We take it seriously enough to explain it properly — and seriously enough to tell you when there's no human trial behind the hype.
8 entries · roughly 1% of what moves the needle
Frontier
Urolithin A
A gut-microbiome metabolite that improves mitochondrial quality — with a few real human RCTs showing modest muscle and endurance effects.
Frontier
NMN & NR
NAD+ precursors that reliably raise a biomarker — with almost no evidence yet that the biomarker translates to living longer or better.
Frontier
Rapamycin
The strongest animal-longevity signal in the field — and almost no human outcome data. A fascinating hypothesis, not a protocol.
Frontier
Spermidine
A dietary polyamine tied to autophagy and, in observational data, to longer life — with human trials still small and early.
Frontier
Resveratrol
The red-wine 'longevity molecule' that launched a thousand supplements and then failed to deliver in humans.
Frontier
BPC-157
A 'healing peptide' with genuinely interesting animal data and essentially no human trials, sold gray-market with unknown safety.
Frontier
GH secretagogues
Sermorelin, ipamorelin and similar peptides that nudge growth-hormone release — marketed for anti-aging on evidence that doesn't exist.
Frontier
Senolytics
Drugs that try to clear 'zombie' senescent cells — one of the most promising longevity ideas, and nowhere near ready to self-administer.